Abstract:Khaled S Allemailem, 1 Mohammed A Alsahli, 1 Ahmad Almatroudi, 1 Faris Alrumaihi, 1 Waleed Al Abdulmonem, 2 Amira A Moawad, 3 Wanian M Alwanian, 1 Nahlah Makki Almansour, 4 Arshad Husain Rahmani, 1 Amjad Ali Khan 5 1 Department of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia; 2 Department of Pathology, College of Medicine, Qassim University, Buraydah, Saudi Arabia; 3 Friedrich-Loeffler-Institut, Institute of Bacterial Infections and Zoonoses, Jena, Germany; 4 Department of Biology, College of Science, University of Hafr Al Batin, Hafr Al Batin, Saudi Arabia; 5 Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, Saudi Arabia Correspondence: Amjad Ali Khan, Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah, 51452, Saudi Arabia, Tel +966-16-3800050 Ext. 15445, Fax +966-16-3801628, Email The recent developments in the study of clustered regularly interspaced short palindromic repeats/associated protein 9 (CRISPR/Cas9) system have revolutionized the art of genome-editing and its applications for cellular differentiation and immune response behavior. This technology has further helped in understanding the mysteries of cancer progression and possible designing of novel antitumor immunotherapies. CRISPR/Cas9-based genome-editing is now often used to engineer universal T-cells, equipped with recombinant T-cell receptor (TCR) or chimeric antigen receptor (CAR). In addition, this technology is used in cytokine stimulation, antibody designing, natural killer (NK) cell transfer, and to overcome immune checkpoints. The innovative potential of CRISPR/Cas9 in preparing the building blocks of adoptive cell transfer (ACT) immunotherapy has opened a new window of antitumor immunotherapy and some of them have gained FDA approval. The manipulation of immunogenetic regulators has opened a new interface for designing, implementation and interpretation of CRISPR/Cas9-based screening in immuno-oncology. Several cancers like lymphoma, melanoma, lung, and liver malignancies have been treated with this strategy, once thought to be impossible. The safe and efficient delivery of CRISPR/Cas9 system within the immune cells for the genome-editing strategy is a challenging task which needs to be sorted out for efficient immunotherapy. Several targeting approaches like virus-mediated, electroporation, microinjection and nanoformulation-based methods have been used, but each procedure offers some limitations. Here, we elaborate the recent updates of cancer management through immunotherapy in partnership with CRISPR/Cas9 technology. Further, some innovative methods of targeting this genome-editing system within the immune system cells for reprogramming them, as a novel strategy of anticancer immunotherapy is elaborated. In addition, future prospects and clinical trials are also discussed. Keywords: CRISPR/Cas9, tumor microenvironment, immune response, molecular targeted therapy, cancer immunotherapy, nanotechnology, clinical study Cancer is well characterized by genomic instability resulting in structural alterations that build up with tumor progression. 1,2 A subpopulation of undifferentiated cancer cells, known as cancer stem cells (CSCs) are found within the tumor bulk. These cells are responsible for cancer initiation, recurrence and show therapeutic resistance and these cells have a potential role in immune surveillance evasion. Recent literature reveals the deeper interplay between CSCs and immune cells within tumor microenvironment (TME), as surprisingly, some major immune cells have a pivotal role in driving the expansion of CSCs. 3 The immune system recognizes the cancer and is poised to eliminate it, but sometimes the immune system is held in check by some inhibitory receptors and ligands. Recent advances in molecular targeted therapy as a novel treatment modality have revolutionized cancer management strategy and taken it to new heights. Different approaches of immunotherapy like immune checkpoint inhibitors (ICIs) and adoptive cell transfer (ACT) have led to satisfying clinical outcomes. However, their efficacies vary and these novel strategies are still very expensive and only a subset of cancer patients have benefited from them. 4 The immune surveillance function of different adaptive and innate immune cells within the TME are suppressed by multiple mechanisms. 5,6 A continuous selective pressure exerted by the host immune response in context of cancer, often results in tumor variants being skilled in surveillance evasion and enable the tumor cells to survive. Some of the known -Abstract Truncated-

A Multiple Targeting Genome Editing System for Remodulation of Circulating Malignant Cells to Eliminate Cancer Immunosuppression and Restore Immune Responses

A Multifunctional Delivery System for Remodulating Cell Behaviors of Circulating Malignant Cells to Prevent Cell Fusion

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Aptamer/Peptide‐Functionalized Genome‐Editing System for Effective Immune Restoration through Reversal of PD‐L1‐Mediated Cancer Immunosuppression

Targeting DNA mismatch repair pathway by CRISPR nanosystem for boosting checkpoint blockade cancer immunotherapy

IDDF2019-ABS-0174 Targeting Monocyte-Intrinsic Enhancer Reprogramming Improves Immunotherapy Efficacy in Hepatocellular Carcinoma

Combination of GNRs-PEI/cGAMP-laden Macrophages-Based Photothermal Induced in Situ Tumor Vaccines and Immune Checkpoint Blockade for Synergistic Anti-Tumor Immunotherapy.

A targeting delivery system for effective genome editing in leukemia cells to reverse malignancy

Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy

Immunostimulatory CKb11 gene combined with immune checkpoint PD-1/PD-L1 blockade activates immune response and simultaneously overcomes the immunosuppression of cancer

A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy

Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation

Synergy of Immunostimulatory Genetherapy with Immune Checkpoint Blockade Motivates Immune Response to Eliminate Cancer

Immune‐check blocking combination multiple cytokines shown curative potential in mice tumor model

Innovative Strategies of Reprogramming Immune System Cells by Targeting CRISPR/Cas9-Based Genome-Editing Tools: A New Era of Cancer Management

Activating Macrophage‐Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles

Multi‐Targeting Nano‐Systems Targeting Heterogenous Cancer Cells for Therapeutics and Biomarker Detection

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Induction of therapeutic immunity and cancer eradication through biofunctionalized liposome-like nanovesicles derived from irradiated-cancer cells

700 Increasing MHC-I expression to potentiate immune checkpoint blockade therapy

On-demand Reprogramming of Immunosuppressive Microenvironment in Tumor Tissue Via Multi-Regulation of Carcinogenic Micrornas and RNAs Dependent Photothermal-Immunotherapy Using Engineered Gold Nanoparticles for Malignant Tumor Treatment